# Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia

> **NCT07044193** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Tamas Vegh, MD** · enrollment: 80 (estimated)

## Conditions studied

- Neuromuscular Blocking Agents
- Residual Neuromuscular Block
- Reversal of Neuromuscular Blockade

## Interventions

- **DRUG:** pipecuronium bromide
- **DRUG:** Rocuronium bromide

## Key facts

- **NCT ID:** NCT07044193
- **Lead sponsor:** Tamas Vegh, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-26
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07044193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07044193, "Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07044193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*